Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide

Laboratory Investigation

Volumn 81, Issue 12, 2001, Pages 1647-1651

  Haapala, Kyllikki ^a   Hyytinen, Eija R ^a   Roiha, Mikko ^a   Laurila, Marita ^a   Rantala, Immo ^a   Helin, Heikki J ^a   Koivisto, Pasi A ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; CYSTEINE; DNA; GLYCINE; ISOLEUCINE; METHIONINE; SERINE; TRYPTOPHAN;

ARTICLE; CANCER HORMONE THERAPY; CANCER RECURRENCE; CARCINOGENESIS; CLINICAL ARTICLE; DNA SEQUENCE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HUMAN; HUMAN TISSUE; MALE; MISSENSE MUTATION; MULTIMODALITY CANCER THERAPY; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE STRAND CONFORMATION POLYMORPHISM; TREATMENT OUTCOME;

EID: 0035212580     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1038/labinvest.3780378     Document Type: Article

References (24)

1. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays
2. Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function
3. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone
4. Endocrine treatment in prostate cancer
5. Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer
6. Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancer
7. Androgen receptor gene and hormonal therapy failure of prostate cancer
8. Androgen receptor gene amplification: A possible molecular mechanism for failure of androgen deprivation therapy in prostate cancer
9. Science behind total androgen blockade: From gene to combination therapy
10. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer
11. Sequence of the intron/exon junctions of the coding region of the human androgen receptor gene and identification of a point mutation in a family with complete androgen insensitivity
12. Ligand responsiveness in human prostate cancer: Structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors
13. PSA decline is an independent prognostic marker in hormonally treated prostate cancer
14. Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials
15. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone
16. Prostate cancer: Molecular biology of early progression to androgen independence
17. Conservative management of prostate cancer
18. Prevalence of androgen receptor gene mutations in latent prostatic carcinomas from Japanese men
19. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist
20. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer
21. Disrupted amino- and carboxyl-terminal interactions of the androgen receptor are linked to androgen insensitivity
22. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence
23. Isolation and characterization of the androgen receptor mutants with divergent transcriptional activity in response to hydroxyflutamide
24. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor